Analysts Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $139.39

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has earned an average recommendation of "Hold" from the fifteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $139.39.

ZBH has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Evercore ISI lifted their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a report on Thursday. Raymond James lifted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an "outperform" rating in a report on Wednesday, January 3rd. JPMorgan Chase & Co. lifted their price target on Zimmer Biomet from $115.00 to $125.00 and gave the company a "neutral" rating in a report on Friday, February 9th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and issued a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.95% of the company's stock.

Hedge Funds Weigh In On Zimmer Biomet

Large investors have recently bought and sold shares of the company. OLD Point Trust & Financial Services N A bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $26,000. Clear Street Markets LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $27,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Lazard Asset Management LLC raised its stake in shares of Zimmer Biomet by 70.5% during the 3rd quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 117 shares in the last quarter. Finally, Naples Money Management LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at $35,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $0.22 during midday trading on Friday, reaching $127.34. 791,725 shares of the company traded hands, compared to its average volume of 1,520,502. The firm has a market cap of $26.16 billion, a PE ratio of 26.04, a PEG ratio of 2.39 and a beta of 1.01. The stock's 50-day simple moving average is $126.39 and its 200-day simple moving average is $118.51. Zimmer Biomet has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analysts' expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business's revenue was up 6.3% on a year-over-year basis. During the same period last year, the business earned $1.88 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.75%. Zimmer Biomet's dividend payout ratio is presently 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.